Background
==========

Atrial fibrillation (AF) is a common complication that occurs after cardiac surgery. The incidence of postoperative atrial fibrillation (POAF) ranges from 10% to 65% depending on the type of surgery, perioperative characteristics, methods of monitoring and the definition of AF \[[@B1],[@B2]\]. Previous studies \[[@B2]-[@B7]\] indicated that AF is associated with prolonged length of hospital stay, risk of stroke, and mortality, thus extensive research has been conducted to explore the mechanism of POAF and identify the effective method for preventing POAF. Beta-blockers and amiodarone are used widely to minimize the risk of POAF and recommended by current guidelines \[[@B8]\]. However, their use requires caution because of potential drug-related side effects. Clinical studies have demonstrated higher inflammatory cytokines level and oxidative damage in patients who developed POAF versus those who did not after undergoing cardiac surgery, suggesting that oxidative stress and inflammatory reaction contribute to POAF \[[@B9]-[@B11]\].

N-acetylcysteine (NAC) is an antioxidant and anti-inflammatory agent, and could reduce cellular oxidative damage and systematic inflammation during cardiac surgery \[[@B12],[@B13]\]. Previous meta-analyses showed that the NAC supplementation effectively reduced the incidence of POAF \[[@B14],[@B15]\]. However, of all the included studies, only one \[[@B12]\] treated POAF as primary endpoint and showed a positive result. Recently, a large trial demonstrated that there was no statistical difference in the incidence of POAF between the NAC and placebo groups \[[@B16]\]. Thus, we conducted an updated meta-analysis to further evaluate the efficacy of NAC on the prevention of POAF in adult patients undergoing cardiac surgery. Besides, we also assessed whether NAC could reduce hospital length of stay, intensive care unit (ICU) stay, all-cause mortality, and cerebrovascular events.

Methods
=======

Literature search
-----------------

A comprehensive search was performed to identify all published randomized controlled trials (RCTs) of NAC versus control during cardiac surgery in any language. PubMed, Embase and Cochrane Central Register of Controlled Trials databases were searched from the date of their inception to 1 July 2013. Searched terms included N-acetylcysteine, acetylcysteine, acetadote, mucomyst, heart surgery, cardiac surgery, cardiothoracic surgery, cardiopulmonary bypass, CPB, coronary artery bypass graft, CABG, valve surgery, valvular surgery and atrial fibrillation.

Inclusion and exclusion criteria
--------------------------------

Only RCTs reporting the use of NAC in the prevention of POAF were included in the meta-analysis (including those reporting the concomitant use of other anti-arrhythmic agents). Exclusion criteria included: (1) duplicated data; (2) laboratory study; (3) abstract, review or letter to editor; and (4) patient age less than 18 years. Based on these criteria, two investigators (Liu and Xu) independently selected studies for further screening by reading title and/or abstract of all identified literatures. All potential eligible studies were obtained for further assessment.

Data extraction
---------------

Two investigators (Liu and Xu) independently extracted the following information from each article: first author's name, year of publication, country of origin, surgery type, perioperative characteristics, NAC protocol, incidence of POAF, length of ICU and hospital stay, all-cause mortality and cerebrovascular events. The primary outcome was the incidence of POAF. The length of hospital and ICU stay, all-cause mortality, and the incidence of cerebrovascular events were considered secondary outcomes. Disagreements were resolved by consensus.

Quality assessment
------------------

The methodological quality of the studies included in the meta-analysis was assessed using validated Jadad 5 point scale \[[@B17]\]. This system emphasizes on the following three parts when defining the quality of a RCT: (1) randomization; (2) blinding; and (3) description of withdrawals and dropouts. A score of one is given for each of the points described. A further point is obtained where the method of randomization and/or blinding is given and is appropriate; where it is inappropriate, a point is deducted. Studies with a score ≤ 2 were considered low quality, and studies with a score \>2 were considered high quality.

Statistical analysis
--------------------

Outcomes were treated as dichotomous (when incidence was reported) or continuous (when the mean and standard deviation were reported) variables. For dichotomous variables, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. For continuous variables, the weighted mean difference (WMD) was calculated. Heterogeneity was explored using I^2^, which describes the percentage of total variation across trials due to heterogeneity rather than chance alone. When I^2^ was more than 50%, significant statistical heterogeneity was considered to be present \[[@B18]\]. Pooled estimates of efficacy were calculated using the fixed-effects model. If there was heterogeneity, the random-effects model was used. Sensitivity analyses were conducted to test the robustness of overall pooled effect. The presence of publication bias was evaluated by using funnel plot. A two-tailed P-value \< 0.05 was considered as significant difference. All statistical analyses were performed using Review Manager version 5.2.

Results
=======

Identification of eligible studies
----------------------------------

One hundred and fifteen articles were identified by the initial literature search, and 90 studies were excluded after title and abstract screening. Therefore, 25 potential relevant studies were retrieved to read the entire manuscript. Fifteen studies were further excluded because they did not treat POAF as an outcome. Consequently, 10 trials (n = 1026 patients) were included in this meta-analysis (Figure [1](#F1){ref-type="fig"}).
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Characteristics of eligible studies
-----------------------------------

Patients' characteristics of the included studies are shown in Table [1](#T1){ref-type="table"}. The number of patients ranged from 20 \[[@B19],[@B20]\] to 240 \[[@B16]\]. Of the 10 RCTs, five trials were conducted in Turkey \[[@B12],[@B19]-[@B22]\], two in Canada \[[@B23],[@B24]\], one in Iran \[[@B16]\], one in Germany \[[@B25]\], and one in Korea \[[@B26]\]. With the use of Jadad 5 point score, all studies were considered high quality. Both male and female were included in all trials. Only one study \[[@B25]\] included some patients with a history of AF. Diabetic mellitus, hypertension, chronic heart failure, and coronary artery disease were the major concomitant diseases. Five trials \[[@B19],[@B20],[@B22],[@B24],[@B26]\] enrolled 228 patients undergoing CABG only, and the remaining 5 trials \[[@B12],[@B16],[@B21],[@B23],[@B25]\] included 798 patients undergoing valve surgery or combination valve surgery with CABG. NAC administration regimen is also presented in detail in Table [1](#T1){ref-type="table"}, with 8 studies \[[@B12],[@B19]-[@B23],[@B25],[@B26]\] using intravenous administration and 2 studies \[[@B16],[@B24]\] using oral administration before cardiac surgery. The duration of NAC administration after cardiac surgery varied from 4 hours \[[@B23]\] to 72 hours \[[@B16]\]. Only one study \[[@B21]\] investigated the efficacy of beta-blocker (carvedilol) with NAC on the prevention of POAF.

###### 

Characteristics of the included studies

  **Reference**               **Jadad score**   **Surgery type**   **Number NAC/control**  **NAC protocol**                                                                                                                **Medical history**                                                        **Previous medication**
  -------------------------- ----------------- ------------------ ------------------------ ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------
  Ozaydin 2008 \[12\]                4            CABG ± valve             58 /57          50 mg/kg iv for 1 h before surgery, then 50 mg/kg/day 48 h after operation                                                      DM, Hypertension, CAD                                                      BRB, ACEI, Statins, Acetylsalicylic acid
  Kazemi 2013 \[16\]                 5            CABG ± valve            120 /120         1200 mg orally 2 times per day from 48 h before and up to 72 h after heart surgery                                              DM,CRF,CAD, CHF, CLD, Hypertension, Hyperlipidemia                         BRB,Statins, ACEI/ARB, Digoxin, Diuretic
  Eren 2003 \[19\]                   3                CABG                 10 /10          100 mg/kg iv for 1 h before and 40 mg/kg/day at 24 h after CPB                                                                  CLD                                                                        Not reported
  Orhan 2006 \[20\]                  3                CABG                 10 /10          50 mg/kg iv at the start of induction of anesthesia for 30 minutes                                                              DM, CAD, Hypertension, Hyperlipidemia                                      Not reported
  Ozaydin 2013 \[21\]                5            CABG ± valve            104 /104         50 mg/kg iv 1 h before and at the same does for 48 h after surgery                                                              CHF, CLD, DM, CAD Hypertension                                             BRB, ACEI/ARB, Statins
  Peker 2008 \[22\]                  4                CABG                 19 /21          50 mg/kg iv 1 h before surgery and 50 mg/kg/day 48 h after the operation                                                        Not reported                                                               Not reported
  Wijeysundera 2007 \[23\]           5            CABG ± valve             88 /87          100 mg/kg iv over 30 min after induction of anesthesia, then 20 mg/kg/h for 4 h after CPB                                       CHF, CLD, DM, CVD, PVD, Hypertension                                       BRB, CCB, ACEI/ARB, NSAIDs
  EI-Hamamsy 2007 \[24\]             3                CABG                 50 /50          600 mg orally the day before and the morning of the operation, 150 mg/kg iv before skin incision, then 12.5 mg/kg/h over 24 h   CHF, CAD                                                                   BRB, CCB, ACEI
  Haase 2007 \[25\]                  5            CABG ± valve             30 /30          150 mg/kg iv after anesthesia induction, then 50 mg/kg iv over 4 h, then 100 mg/kg iv over 20 h                                 DM, CLD, CAD, PVD, Stroke, Hypertension, Hyperlipidemia, Carotid disease   Not reported
  Kim 2011 \[26\]                    4                CABG                 24 /24          100 mg/kg iv bolus after anesthetic induction, then 40 mg/kg/day iv for 24 h                                                    DM, Hypertension                                                           BRB, CCB, ACEI, Diuretics

ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; BRB, beta-receptor blocker; CAD, coronary artery disease; CCB, calcium channel blocker; CHF, chronic heart failure; CLD, chronic lung disease; CRF, chronic renal failure; SD, standard deviation; DM, diabetes mellitus; CVD, cerebrovascular disease; NSAIDs, non-steroid anti -inflammatory drugs; PVD, peripheral vascular disease.

Incidence of POAF
-----------------

The data of the included studies are shown in Table [2](#T2){ref-type="table"}. The method of monitoring and the definition of POAF are presented in Table [3](#T3){ref-type="table"}. Of the 10 trials, only four \[[@B12],[@B16],[@B21]\] treated POAF as their primary endpoint.

###### 

Outcomes of included studies in the meta-analysis

  **Reference**                   **POAF**   **Duration of ICU (hours)**   **Hospitalization (days)**   **Mortality**   **Nonfatal CBV**                                       
  ------------------------------ ---------- ----------------------------- ---------------------------- --------------- ------------------ ------------ ------- ------- ------- -------
  Ozaydin 2008 \[[@B12]\]           3/58                12/57                          NA                    NA             7.7 ± 3        7.9 ± 4.2    0/58    2/57    1/58    0/57
  Kazemi 2013 \[[@B16]\]           14/120              19/120                      120 ± 45.6           115.2 ± 79.2       7.4 ± 1.3       7.2 ± 0.9    1/120   2/120   1/120   1/120
  Eren 2003 \[[@B19]\]              2/10                1/10                           NA                    NA                NA              NA       0/10    0/10    0/10    0/10
  Orhan 2006 \[[@B20]\]             0/10                1/10                      23.2 ± 1.75            22.6 ± 1.84       7.2 ± 0.42      7.3 ± 0.48   0/10    0/10     NA      NA
  Ozaydin 2013 \[[@B21]\]          9/104               25/104                          NA                    NA                NA              NA       1/104   2/104   2/104   0/104
  Peker 2008 \[[@B22]\]             0/19                2/21                           NA                    NA                NA              NA       0/19    0/21    0/19    0/21
  Wijeysundera 2007 \[[@B23]\]     50/88                58/87                         45.6                 40.8\*          8 (6--12)       8 (6--12)†   0/88    7/87    4/88    4/87
  EI-Hamamsy 2007 \[[@B24]\]        4/50                6/50                           NA                    NA            5.4 ± 2.3       5.3 ± 2.5    3/50    0/50    0/50    0/50
  Haase 2007 \[[@B25]\]            19/30                16/30                          44                   45\*            8(7--11)       8(7--11)†    0/30    1/30     NA      NA
  Kim 2011 \[[@B26]\]               4/24                8/24                        72 ± 36              81.6 ± 50.4       11.3 ± 6.3      10.5 ± 4.5   0/24    2/24    0/24    0/24

Data are number or mean ± deviation; CBV, cerebrovascular events; NA, data not available; \*values expressed as median; †data expressed as median (interquartile range).

###### 

POAF outcome definition and assessment

  **Reference**                  **Method of atrial fibrillation assessment**                                                                                                                 **Definition of atrial fibrillation**
  ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------
  Ozaydin 2008 \[[@B12]\]        ECGs performed continuously at the first 2 postoperative days in the ICU, and 2 times a day routinely when new symptom developed or observed in the wards.   An irregular narrow complex rhythm with absence of discrete p-waves lasting longer than 5 minutes
  Kazemi 2013 \[[@B16]\]         Holter performed continuously for 72 h after surgery                                                                                                         More than 5 minutes of AF or associated with hemodynamic compromise requiring therapy immediately.
  Eren 2003 \[[@B19]\]           ECGs were recorded on the first postoperative day                                                                                                            Not reported
  Orhan 2006 \[[@B20]\]          Not reported                                                                                                                                                 Not reported
  Ozaydin 2013 \[[@B21]\]        ECGs performed continuously during ICU stay and all-day Holter was used during the rest of hospitalization.                                                  The incidence of AF lasting longer than 5 minutes during hospitalization
  Peker 2008 \[[@B22]\]          ECGs conducted continuously during the first 2 postoperative days in the ICU, and 2 times per day routinely when new symptom developed or noted              Not reported
  Wijeysundera 2007 \[[@B23]\]   Continuous telemetry or 12-lead ECGs                                                                                                                         Any new atrial fibrillation
  EI-Hamamsy 2007 \[[@B24]\]     Not reported                                                                                                                                                 Not reported
  Haase 2007 \[[@B25]\]          Not reported                                                                                                                                                 Not reported
  Kim 2011 \[[@B26]\]            Not reported                                                                                                                                                 Not reported

ECG, electrocardiogram.

Pooling all ten RCTs, 20.5% (105 of 513) of patients given NAC and 28.8% (148/513) of controls developed POAF. The meta-analysis of ten trials using a fixed-effects model showed that NAC reduced the incidence of POAF (OR 0.56, 95% CI 0.40 to 0.77; *P* \< 0.001; Figure [2](#F2){ref-type="fig"}) compared with controls, with no heterogeneity between the studies (I^2^ = 15%, *P* = 0.31).
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Sensitivity analyses were conducted to test the robustness of the main analysis. We tested whether excluding small sample studies (n \<60 patients) \[[@B19],[@B20],[@B22],[@B26]\] would change the direction of the overall result. The meta-analysis of the remaining studies (OR 0.57, 95% CI 0.40 to 0.80; *P* = 0.001) \[[@B12],[@B16],[@B21],[@B23]-[@B25]\] was similar to the overall result, with little statistical heterogeneity (I^2^ = 42%, *P* = 0.12). A trial \[[@B25]\] enrolled some patients with a history of AF, but the pooled results (OR 0.50; 95% CI 0.35 to 0.71; *P* \< 0.001; I^2^ = 0%, *P*~heterogeneity~ = 0.56) did not change when this trial was exclude. In addition, we tested whether different duration of NAC supplementation after cardiac surgery would alter the direction of the overall result. Using the fixed-effects model, the meta-analysis of studies (OR 0.40; 95% CI 0.25 to 0.65; *P* \< 0.001; I^2^ = 22%, *P*~heterogeneity~ =0.28; Figure [3](#F3){ref-type="fig"}) \[[@B12],[@B16],[@B21],[@B22]\] with a long-term (lasting for 48 h-72 h after operation) was similar to the overall effects (OR 0.56, 95% CI 0.40 to 0.77). However, it failed to reduce the incidence of POAF with a short-term NAC (within 24 h after surgery) supplementation (OR 0.64; 95% CI 0.39 to 1.06; *P* = 0.09; I^2^ = 0%, *P*~heterogeneity~ =0.7; Figure [4](#F4){ref-type="fig"}) \[[@B19],[@B23]-[@B26]\].
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Length of ICU stay
------------------

Five studies \[[@B16],[@B20],[@B23],[@B25],[@B26]\] reported the data of ICU length of stay, while only three \[[@B16],[@B20],[@B26]\] studies reported the values as mean ± standard deviation. All the data were converted from days into hours for analysis. Prophylactic NAC was not associated with a reduction in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16; *P* = 0.45). No heterogeneity of included studies was noted (I^2^ = 0%, *P* = 0.64).

Hospital length of stay
-----------------------

Five \[[@B12],[@B16],[@B20],[@B24],[@B26]\] studies reported values as mean ± standard deviation, two \[[@B23],[@B25]\] expressed data as median and interquartile range, and one \[[@B21]\] showed values by bar graph. The meta-analysis of the five studies using a fixed-effects model presented that NAC treatment did not reduce the length of hospital stay (WMD 0.09; 95% CI −0.13 to 0.31; *P* = 0.40; Figure [5](#F5){ref-type="fig"}). No statistical heterogeneity was observed across studies (I^2^ = 0%, *P* = 0.76).
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All-cause mortality
-------------------

Death occurred in 5 of 513 patients (0.9%) treated with NAC and in 16 of 513 patients (3.1%) treated with placebo. Use of NAC was associated with a reduction in all-cause death (OR 0.40; 95% CI 0.17 to 0.93; *P* = 0.03; I^2^ = 0%, *P*~heterogeneity~ =0.44; Figure [6](#F6){ref-type="fig"}).
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Incidence of cerebrovascular events
-----------------------------------

Seven \[[@B12],[@B16],[@B19],[@B21]-[@B23],[@B26]\] studies reported the incidence of cerebrovascular events after operation. Cerebrovascular events occurred in 8 of 423 patients (1.9%) treated with NAC and in 5 of 424 patients (1.2%) treated with placebo. Prophylactic use of NAC failed to present a reduction in cerebrovascular accidents (OR 1.68; 95% CI 0.60 to 4.69; *P* = 0.32; I^2^ = 0%, *P*~heterogeneity~ =0.64).

Publication bias
----------------

The funnel plot for the incidence of POAF was shown in Figure [7](#F7){ref-type="fig"}. The funnel plot appeared symmetrical, suggesting that there was no potential publication bias among the included trials.
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Discussion
==========

This meta-analysis shows that prophylactic NAC can reduce the incidence of POAF in adult patients undergoing cardiac surgery, with a conclusion similar to the previous meta-analyses \[[@B14],[@B15]\]. However, the meta-analysis of trials (OR 0.64; 95% CI 0.39 to 1.06) using a short-term NAC administration, differing from the pooled effect of studies with a long-term (OR 0.51; 95% CI 0.33 to 0.79), demonstrates that there is no significant difference compared with controls. These findings suggest that NAC can be used for adult patients undergoing cardiac surgery to prevent POAF. It would be more reasonable to prolong the duration of NAC administration up to postoperative day 2--3. Previous studies presented that on postoperative day 2--3 the inflammatory cytokines levels are the highest, corresponding to the day of the highest incidence of POAF \[[@B7],[@B27]\]. To some extent, the different results between short-term and long-term NAC administration may be associated with the anti-inflammatory property of NAC. Additionally, NAC has a generally good safety profile \[[@B16],[@B21],[@B23]\]. Of the 10 included studies, only one \[[@B23]\] reported evident side effects among patients, but there was no statistical difference when compared with control group.

An increasing body of evidence demonstrates that oxidative stress and inflammatory reaction play an important role in the pathophysiology of POAF \[[@B7],[@B9],[@B28]\]. Antioxidants, including NAC, have proved to decrease serum levels of molecules markers of cellular oxidative stress in patients undergoing heart surgery \[[@B9]-[@B11],[@B16],[@B28],[@B29]\]. NAC is a glutathione precursor, by entering cells and being hydrolyzed to cysteine, it stimulates glutathione synthesis \[[@B12],[@B16]\]. In this way, it increases the level of intracellular reduced glutathione, which is often depleted as a response to increased status of inflammation reaction and oxidative stress \[[@B16],[@B30]\]. In addition to that, it may also block renin angiotensin system and/or atrial remodeling via its antioxidant actions and anti-inflammatory \[[@B12],[@B20],[@B31]\]. Thus, NAC is a potential agent used for reducing the incidence of POAF in adult patients undergoing cardiac surgery.

Although POAF is often considered both transient and self-limiting \[[@B7],[@B15]\], it can increase the length of ICU and hospital stay, cerebrovascular events, and mortality \[[@B3]-[@B7]\]. With regard to ICU and hospital stay, the pooled effects are similar to the pre-existing meta-analyses \[[@B13]-[@B15]\], showing no significant difference compared with controls. There is also no significant reduction in the risk of cerebrovascular events (OR 1.68; 95% CI 0.60 to 4.69) between two groups. This meta-analysis, however, demonstrates that prophylactic NAC apparently reduce the occurrence of all-cause mortality (OR 0.40; 95% CI 0.17 to 0.93), which differs from the previous meta-analysis (OR 0.81; 95% CI 0.39 to 1.68) conducted by Wang et al. \[[@B13]\].

There are several limitations to this meta-analysis that should be noted. First, there is significant heterogeneity in both the methods of monitoring and the definition of POAF between the studies. AF following cardiac surgery was reported as a clinical outcome in seven studies \[[@B19],[@B20],[@B22]-[@B26]\], and only three studies \[[@B12],[@B16],[@B21]\] treated POAF as a primary endpoint. All these may lead to potential overestimation or underestimation of the true incidence of POAF. Second, for the POAF endpoint, the use of beta-blockers and amiodarone was not the standard therapy among most included studies \[[@B12],[@B16],[@B19],[@B20],[@B22]-[@B26]\]. Meanwhile, the adjunctive use of NAC in addition to these proven prophylactic strategies is not known. An adjunctive prophylactic protocol, however, that might further prevent POAF without reducing blood prssure and/or heart rate. As such, Ozaydin and his colleagues demonstrated that carvedilol plus NAC significantly reduced the incidence of POAF compared with carvedilol plus placebo \[[@B21]\]. Next, due to different NAC doses and schedules used in these trials, we are unable to evaluate this heterogeneity on clinical outcomes and identify an optimal NAC dose from this meta-analysis. Finally, the positive effect seen is based almost entirely on two trials from the same group \[[@B12],[@B21]\], however, the results of which have not been re-produced in the majority of the other trials.

Future studies should aim to treat the incidence of POAF as a primary endpoint, and standardize the definition of POAF. In addition, these studies should compare various does of NAC, including varying lengths of therapy. It is also important to assess the impact of NAC supplementation on the top of already proven agents for preventing POAF, including beta-blockers, amiodarone, and any other potential prophylaxis.

Conclusions
===========

This meta-analysis shows that prophylactic use of NAC could reduce the incidence of POAF and all-cause mortality for adult patients undergoing cardiac surgery. However, larger RCTs evaluating these and other postoperative complication endpoints are needed.
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